Cryogenic-electron microscopy structures of human NLRP6 monomer in the adenosine-5'-triphosphate (ATP)/NBD-bound (twisted conformation) and unbound (extended conformation) states reveal the ATP-mediated cooperative inhibition mechanism of NLRP6 and provide insight into the therapeutic intervention of NLRP6-related autoinflammatory disorders.
Abstract
Inflammasomes ignite innate immune defense in response to infectious pathogens and noninfectious dangers, primarily through sensors composed of nucleotide-binding domain (NBD), leucine-rich repeat (LRR)-containing (NLR) family proteins. NLRP6 is an inflammasome sensor that plays critical roles in regulating intestinal inflammation, and its overactivation is linked to autoinflammatory diseases such as inflammatory bowel disease. However, how NLRP6 is maintained in an inhibited structure is unknown. Here we report two cryogenic-electron microscopy structures of human NLRP6 monomer in the adenosine-5'-triphosphate (ATP)/NBD-bound (twisted conformation) and unbound (extended conformation) states. The ATP-binding event connects and compacts the NACHT subdomains and the LRR domain, thus maintaining NLRP6 in an inhibitory conformation. NBD interacts directly with helical domain 1, winged-helix domain and helical domain 2, further contributing to the autoinhibition. Disruption of ATP binding and NBD interactions unleashes the NLRP6 inflammasome activation in the cellular study. The structural comparison between twisted and extended conformations reveals that the rearrangement of an NLRP6-specific acidic loop modulates NLRP6 activity. Although ATP-binding of NLRP6 and MCC950 (a potent NLRP3 inhibitor)-binding of NLRP3 share a similar interaction location in the structures, MCC950 does not inhibit NLRP6 in cells. Together, our data reveal the ATP-mediated cooperative inhibition mechanism of NLRP6 and provide insight into the therapeutic intervention of NLRP6-related autoinflammatory disorders.
A critical role is uncovered for intrinsically disordered regions (IDRs) in activating NLRP1, NLRP3, and NLRP14 inflammasomes, suggesting that targeting the dynamics of phase transitions could open novel therapeutic avenues for treating inflammatory and autoimmune diseases.
Teresa Nava-Ramírez, C. Cuevas-Velazquez, Alejandra A. Covarrubias et al.· Frontiers in Immunology· 0 citations
Vilazodone exerted anti-inflammatory effects in vivo, reducing cytokine production in mouse models of MSU-induced peritonitis and LPS-induced systemic inflammation and highlight its potential for repurposing in inflammasome-driven diseases.
Xiang-Yu Yang, Gui-Fang Xiong, Jie Yang et al.· International Immunopharmaco...· 0 citations
The NLRP3 inflammasome is a cytoplasmic multiprotein complex that is activated under stress or infection conditions. It promotes the maturation of IL-1β by cleaving pro-Caspase-1, thereby playing a critical role in host innate immune responses. Various viruses can differentially activate NLRP3 through distinct mechanis...
Li-Fang Cao, Run-Bin Huang, Lu Yang et al.· Fish and Shellfish Immunolog...· 0 citations
Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE). The nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome plays a central role in the pathogenesis of LN. Aberrant activation of the NLRP3 inflammasome directly promotes glomerula...
Hong-Fei Sun, Xin-Ran Xie, Ming-Ru Ma et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.